Free radicals linked to heart damage caused by cancer
In fruit flies, antioxidants reverse tumor-related cardiac dysfunction. Ohio State University A new study in animal models shows that the presence of a cancer tumor alone can lead… read more.
In fruit flies, antioxidants reverse tumor-related cardiac dysfunction. Ohio State University A new study in animal models shows that the presence of a cancer tumor alone can lead… read more.
Ground-breaking Phase III head-to-head DESTINY-Breast03 results featured at ESMO Presidential Symposium support Enhertu as the potential new standard of care in previously treated patients. DESTINY-Breast01 Phase II trial… read more.
Updated results from the CASPIAN Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained,… read more.
BUFFALO, N.Y. — Having second- or third-degree relatives with colorectal cancer increases a person’s risk of developing the disease, according to the findings of a study led by… read more.
Massachusetts Institute of Technology MIT engineers, in collaboration with scientists at Cancer Research UK Manchester Institute, have developed a new way to grow tiny replicas of the pancreas,… read more.
The NHS will launch the world’s largest trial of a revolutionary new blood test that can detect more than 50 types of cancer before symptoms appear. The first… read more.
MacroGenics announced the final overall survival (OS) results of the SOPHIA Phase III study of Margenza (margetuximab-cmkb) in adult patients with metastatic HER2-positive breast cancer. The final OS… read more.
In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters. Targeting these T cells, which are… read more.
Too many “exhausted” T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukaemia (CLL) make it more challenging for chimeric antigen… read more.
One infusion of an investigative chimeric antigen receptor-T cell therapy (CAR-T cell therapy) for multiple myeloma has produced early and durable responses in heavily pretreated patients, researchers reported… read more.
Bristol Myers Squibb announced that the European Commission has granted Conditional Marketing Authorization for Abecma (idecabtagene vicleucel; ide-cel), a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)… read more.
Genentech/Roche announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab) as adjuvant treatment following surgery and platinum-based… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.